4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion
Press Release
4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion
London, United Kingdom, 17 March 2025 – 4BIO Capital ('4BIO' or 'the Group'), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Araris Biotech AG ('Araris' or 'the Company'), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs) has entered into an agreement to be acquired by Taiho Pharmaceutical Co., Ltd ('Taiho Pharmaceutical'). The acquisition follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023 and is expected to be completed in the first half of 2025.
Under the terms of the agreement, Taiho Pharmaceutical will pay a USD 400 million upfront, with the potential for additional milestone payments of up to USD 740 million, and for a total amount of up to USD 1.14 billion.
Araris has been an investment out of 4BIO Capital Fund II, and the 4BIO team is proud to have actively supported the fast development and acquisition since the initial investment in 2020. In early 2020, 4BIO Capital recognised the significant potential of next-generation ADCs, however came to the conclusion that linker technologies needed to be improved to take the field to the next level. The 4BIO team subsequently identified Araris as the best-in-class linker-payload ADC platform to address the shortcomings of current generation ADCs. The Company's AraLinQ™ technology enables the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, whilst ensuring long-term stability and safety of the resulting ADC, as well as increased antitumour effect compared to conventional ADCs. 4BIO Capital supported the company in the development of AraLinQ™ and its proprietary pipeline, leading its Series A in 2022 and supporting the company through multiple large pharma partnerships both as an investor and from the Board with Managing Partner Dima Kuzmin as Chairman, and Brian McVeigh and Dr Therese Liechtenstein as Board Observers.
Araris is advancing three products for the treatment of haematological and solid tumours developed using its unique AraLinQ™ technology, all of which are currently in the preclinical stage. These products are anticipated to enter into clinical trials between 2025 and 2026 and will benefit from Taiho Pharmaceutical's clinical development expertise.
Dr Dmitry (Dima) Kuzmin, Managing Partner at 4BIO Capital and Chairman of Araris, commented, 'The success of Araris is a perfect example of the 4BIO Capital playbook. We identified the technological hurdle that needed to be overcome to empower an up-and-coming drug class, identified the best science and the people to solve it and, alongside Araris' management team, supported the company to secure multiple pharma partnerships, develop its own pipeline and now become part of the Taiho group. This acquisition confirms Araris' position as one of the most exciting ADC companies in the market and has the potential to return over two times the fund to 4BIO Ventures II investors, further validating our science-driven, high conviction seed investment strategy.'
Dr Dragan Grabulovski, Chief Executive Officer and co-founder of Araris added, 'We sincerely appreciate the support of Dima and the entire team at 4BIO in shaping our company, advancing our science, and helping us reach this important milestone. It's the kind of investor that brings not only money to the table but also valuable strategic guidance, a network of industry connections, and a shared vision for transforming cancer treatment. Araris has developed a unique ADC technology that delivers different cancer-fighting drugs directly to tumours with high precision. This approach allows multiple treatment methods to work together at the same time while reducing harmful side effects. We are excited to join forces with Taiho Pharmaceutical whose deep expertise in oncology will be instrumental in accelerating the clinical development of our promising ADC candidates for both haematological and solid tumours.'
Philippe Fauchet OBE, Venture Partner at 4BIO Capital added, 'We are delighted to see a seed investment we made in Europe find a skilled partner in a pioneering Japanese pharma company and are very happy to have facilitated the closer partnership. This deal further validates our strategy of building strong bridges between the Japanese and European biotech and pharma companies, which we believe will bring significant benefits to both ecosystems.'
Details of the acquisition can be found in the press release from Araris and Taiho Pharmaceutical here.
– End –
Contacts
4BIO Capital
+44 (0) 203 427 5500info@4biocapital.com
ICR HealthcareAmber Fennell, Jonathan Edwards, Kris Lam
+44 (0)20 3709 57004biocapital@icrhealthcare.com
About 4BIO Capital
4BIO Capital ('4BIO') is an international venture capital firm focused on investing in advanced therapies, including genomic medicines and other emerging technologies, to unlock the treatments of the future. 4BIO's objective is to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, connect with us on LinkedIn and Twitter @4biocapital and visit www.4biocapital.com.
About Araris Biotech AG
Araris Biotech is a leading independent company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris' vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy. By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of smart missiles that deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance. Araris' investors include 4BIO Capital, b2venture, Pureos Bioventures, Redalpine, Schroders Capital, VI Partners, Wille AG, Institute for Follicular Lymphoma Innovation and Samsung Ventures.
For more information about our science and pipeline, please visit https://www.ararisbiotech.com
About Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases. Its corporate philosophy takes the form of a pledge: 'We strive to improve human health and contribute to a society enriched by smiles.' In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people's efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en/Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
US will resume accreditation of Swiss investment advisers
(Reuters) -The U.S. will resume processing applications from Swiss entities aiming to become registered investment advisers in the U.S., the U.S. Securities and Exchange Commission and Swiss financial market regulator FINMA said in separate statements on Tuesday. SEC had suspended new registrations for several years and would lift the ban with immediate effect after the watchdogs agreed on a direct transmission of information from Swiss institutions to SEC staff and on-site examinations, the statements said. "I am very pleased to announce that the SEC stands ready to provide prompt consideration of the registration applications from Swiss investment advisers," SEC Chairman Paul S. Atkins said. "I thank my FINMA counterparts for their collaboration and welcome their actions to make this possible." Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Cleaning Products Market Size to worth USD 254.54 Billion by 2032, says Coherent Market Insights
Burlingame, CA, June 11, 2025 (GLOBE NEWSWIRE) -- The global Cleaning Products Market size was valued at USD 163.45 Billion in 2025 and is expected to reach USD 254.54 Billion by 2032, growing at a compound annual growth rate (CAGR) of 6.53% from 2025 to 2032. Consumers are increasingly seeking convenient cleaning products that offer effective surface cleaning and disinfection. Advances in cleaning formulations—designed to eliminate more germs in less time—along with the introduction of multifunctional products, are expected to further propel market growth. Request Sample Pages: Global Cleaning Products Market Key Takeaways According to Coherent Market Insights (CMI), the global cleaning products market size is forecast to expand from USD 163.45 Bn in 2025 to a staggering USD 254.54 Bn by 2032. Global demand for cleaning products will likely increase at a steady CAGR of 6.5% throughout the assessment period. By product type, surface cleaners segment is projected to generate a revenue of around USD 61.13 Bn in 2025. Based on application, toilet segment is expected to account for nearly one-fifth of the global cleaning products market share in 2025. By end user, commercial segment is anticipated to dominate the industry, generating a revenue of around USD 92.34 Bn by 2025. Asia Pacific is expected to remain the leading consumer of cleaning products, owing to rising hygiene awareness, rapid urbanization, and increasing government initiatives. The region is set to account for nearly one-third of the global cleaning products market revenue share in 2025. As per Coherent Market Insights' latest cleaning products market analysis, Middle East is expected to exhibit fastest-growth during the assessment period. It will likely account for more than 1/4 of the total revenue share in the cleaning products market by 2025. Growing Health and Hygiene Awareness Spurring Market Growth Coherent Market Insights' latest cleaning products market report highlights major factors driving the industry's growth. Increasing awareness about health and hygiene is one such prominent growth driver. The looming threat of disease outbreaks, like that of COVID-19, has significantly heightened public consciousness regarding the importance of cleanliness. This shift in consumer behavior is expected to drive demand for cleaning products across residential and commercial sectors. Modern consumers now prioritize maintaining hygienic environments in homes, workplaces, and public spaces. As a result, they increasingly use cleaning products like surface cleaners and disinfectants to eliminate pathogens like viruses and bacteria, thereby fostering market growth. Also Read: Surface Disinfectant Market Size, Share & Trend Analysis Report (2025-2032) Environmental Concerns and Counterfeit Products Limiting Market Growth The prospective cleaning products market outlook looks optimistic. However, growing environmental concerns and penetration of counterfeit cleaning products might limit market growth to some extent. Many cleaning products contain harmful chemicals which can cause health issues and environmental pollution. This has led to heightened consumer awareness and regulatory scrutiny, which could reduce the overall cleaning products market demand. Counterfeit cleaning products are increasingly making their way into the market, affecting consumer trust and brand loyalty. This infiltration can also negatively impact the cleaning products market growth during the forecast period. Expanding Usage in Hospitality and Healthcare Sectors Unlocking New Opportunities More stringent cleanliness and hygiene standards are being enforced in hotels, hospitals, and public spaces to improve public safety and health. This is driving increased use of cleaning products in these areas, thereby creating lucrative growth opportunities for cleaning product manufacturers. Increasing number of nuclear families, especially in developed and developing nations, will also positively impact sales of cleaning products. This is because every household needs its own set of cleaning supplies like toilet cleaners, laundry detergents, and dishwashing products. Purchase Now Up to 25% Discount on This Premium Report @ Impact of AI Trend on the Cleaning Products Market Artificial Intelligence (AI) is significantly influencing the cleaning products market. It helps cleaning product manufacturers streamline operations, accelerate product innovation, and enhance customer engagement. Companies use AI-driven insights to predict consumer preferences, optimize supply chains, and develop eco-friendly, efficient cleaning formulations. Smart cleaning technologies like AI-powered robotic cleaners and automated dispensing systems are also gaining traction, further boosting demand for compatible cleaning products. Unilever leads from the forefront when it comes to AI adoption. The company recently launched a new line of AI-integrated systems under its 'Clean Future' initiative. These new systems use AI to analyze user cleaning habits as well as optimize detergent usage in real time. Emerging Cleaning Products Market Trends Ongoing product innovation is a key growth-shaping trend in the market. Companies are constantly innovating to stand out from the crowd. For instance, they are focusing on developing multi-purpose, convenient, and user-friendly cleaning products to align with evolving consumer preferences and lifestyles. Sustainability is another prominent trend in the cleaning products industry. Modern consumers demand sustainable and eco-friendly products. This is prompting cleaning product manufacturers to use natural or plant-based ingredients and recyclable or biodegradable packaging. Growing popularity of these sustainable cleaning products will bode well for the target market. Cleaning product companies are also integrating smart technologies like automated dispensers to improve convenience as well as user experience. These innovations are expected to boost growth of the cleaning products market in the coming years. Rising online sales of cleaning products will continue to provide a strong thrust for market expansion. Online platforms are making it easier for consumers to access a wide range of cleaning products. Also Read: Detergent Chemicals Market Size, Share, Trends, & Opportunities (2025-2032) Analyst's View said a senior analyst at CMI. Current Events and Their Impact on the Cleaning Products Market Event Description and Impact Post-Pandemic Shift to Preventive Hygiene Description: People are realizing the importance of cleanliness and hygiene, particularly after the COVID-19 pandemic, to tackle disease spread. Impact: There is a significant demand for hospital-grade disinfectants, multi-surface sanitizers, antiviral sprays, and long-lasting antimicrobial coatings. Rising Demand for Sustainable and Biodegradable Products Description: Stricter global regulations as well as consumer demand are driving a shift away from harsh chemicals toward eco-friendly, refillable products. Impact: Many brands are investing in plant-based surfactants, enzyme-based cleaners, and waterless formulations, as well as launching refill stations and subscription models to reduce plastic waste. Digital Transformation & Expanding E-commerce Description: Rise in e-commerce, triggered by pandemic lockdowns, has made online channels primary sales drivers for cleaning products. Impact: Brands use data analytics to personalize offers, while D2C models and influencers shape consumer choices. Competitor Insights Key companies in cleaning products market research report: Unilever PLC Procter & Gamble Co. 3M Company Henkel AG & Co. KGaA SC Johnson & Son, Inc. Colgate-Palmolive Company Clorox Company Ecolab Inc. Reckitt Benckiser Group PLC Kao Corporation Kimberly-Clark Corporation S.C. Johnson Professional Church & Dwight Co., Inc. Diversey Holdings, Ltd. Amway Corporation Key Developments In April 2025, Unilever introduced the Cif Infinite Clean, a new cleaning spray that uses pioneering bioscience technology and natural power of probiotics to keep homes cleaner for longer. In August 2024, Ecolab announced the availability of its four new cleaning solutions, including Ammonia-Free Pro Glass Cleaner and Multi-Surface Cleaner Spray Bottle and Wood Deck and Fence Pressure Wash Concentrate Outdoor Cleaner, through online and in stores throughout North America. In April 2024, The Clorox Company expanded its cleaning products portfolio with the launch of several new solutions. These include Pine-Sol Concentrated Multi-Surface Cleaners and Clorox Foaming Toilet Bomb Toilet Bowl Cleaners, among others. Get Customization on this Report: Market Segmentation Product Type Insights (Revenue, USD Bn, 2020 - 2032) Surface Cleaners Laundry Detergents Dishwashing Products Toilet Cleaners Others Application Insights (Revenue, USD Bn, 2020 - 2032) Toilet Kitchen Floor Surface Laundry Hand/Personal Care Others End-user Insights (Revenue, USD Bn, 2020 - 2032) Household Commercial Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032) Supermarkets/Hypermarkets Online Retail Convenience Stores Others Regional Insights (Revenue, USD Bn, 2020 - 2032) North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa Central Africa Also Read: Contract Cleaning Services Market Size, Share, Trends & Opportunities (2025-2032) Our Trusted Partners: Worldwide Market Reports, Coherent MI, Stratagem Market Insights Get Recent News: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. For Latest Update Follow Us:LinkedIn | Facebook | TwitterError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Canadian court orders NOVA Chemicals to pay Dow an additional CAD$1.6 billion judgment
MIDLAND, Mich., June 11, 2025 /PRNewswire/ -- The Court of King's Bench of Alberta, Canada has issued a judgment ordering NOVA Chemicals Corporation to pay Dow (NYSE: DOW) an additional amount of CAD$1.620 billion (equivalent to approximately USD$1.2 billion) in damages. The judgment, signed on June 10, 2025, relates to losses Dow incurred from the companies' jointly owned ethylene asset in Joffre, Alberta, Canada. The award includes interest to April 7, 2025, but excludes subsequent interest or legal costs. Payment is anticipated to occur in the fourth quarter of 2025. This latest ruling and award of damages to Dow is in addition to a prior payment by NOVA to Dow of CAD$1.43 billion (approximately USD$1.08 billion) in damages in 2019 following a June 2018 decision. That decision found NOVA had failed to operate the jointly owned ethylene asset at full capacity and had breached contractual obligations since 2001, resulting in reduced ethylene to Dow. On appeal, the court directed that Dow's damages be recalculated for the period from 2001 through 2012, as well as for the period from 2013 through June 2018, which had not yet been quantified. The judgment is subject to appeal. About DowDow (NYSE: DOW) is one of the world's leading materials science companies, serving customers in high-growth markets such as packaging, infrastructure, mobility and consumer applications. Our global breadth, asset integration and scale, focused innovation, leading business positions and commitment to sustainability enable us to achieve profitable growth and help deliver a sustainable future. We operate manufacturing sites in 30 countries and employ approximately 36,000 people. Dow delivered sales of approximately $43 billion in 2024. References to Dow or the Company mean Dow Inc. and its subsidiaries. Learn more about us and our ambition to be the most innovative, customer-centric, inclusive and sustainable materials science company in the world by visiting For further information, please contact: Glynna Mayersgmayers@ X: Facebook: LinkedIn: Instagram: ®TM Trademark of The Dow Chemical Company ("Dow") or an affiliated company of Dow View original content to download multimedia: SOURCE The Dow Chemical Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
